CD274 and small cell lung carcinoma: For example, the combination of anti-PDL-1 antibody with platinum-based doublet chemotherapy has emerged as first-line therapy for a wide range of SCLC.[7] Unfortunately, only a subset of SCLC patients seemed to obtain benefit.[8] One study evaluated the efficacy and safety of ipilimumab in combination with etoposide and platinum in extensive stage SCLC patients, but the overall survival of patients was not significantly prolonged following treatment.[9] It has been showed that the tumor microenvironment (TME) may be associated with the efficacy of immunotherapy for SCLC.